Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Cervical Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 263 articles:
HTML format



Single Articles


    January 2021
  1. CHISALE MABOTJA M, Levin J, Kawonga M
    Beliefs and perceptions regarding cervical cancer and screening associated with Pap smear uptake in Johannesburg: A cross-sectional study.
    PLoS One. 2021;16:e0246574.
    PubMed     Abstract available


  2. MANYAU PMC, Mabeka M, Mudzviti T, Kadzatsa W, et al
    Renal function impairment in cervical cancer patients treated with cisplatin-based chemoradiation: A review of medical records in a Zimbabwean outpatient department.
    PLoS One. 2021;16:e0245383.
    PubMed     Abstract available


  3. DEVINE A, Vahanian A, Sawadogo B, Zan S, et al
    Costs and cost-effectiveness of cervical cancer screening strategies in women living with HIV in Burkina Faso: The HPV in Africa Research Partnership (HARP) study.
    PLoS One. 2021;16:e0248832.
    PubMed     Abstract available


  4. BOGALE AL, Teklehaymanot T, Haidar Ali J, Kassie GM, et al
    Knowledge, attitude and practice of cervical cancer screening among women infected with HIV in Africa: Systematic review and meta-analysis.
    PLoS One. 2021;16:e0249960.
    PubMed     Abstract available


  5. NGCAMPHALALA C, Ostensson E, Ginindza TG
    The economic burden of cervical cancer in Eswatini: Societal perspective.
    PLoS One. 2021;16:e0250113.
    PubMed     Abstract available


  6. JUBAIR L, Lam AK, Fallaha S, McMillan NAJ, et al
    CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice.
    PLoS One. 2021;16:e0223288.
    PubMed     Abstract available


  7. PENG L, Hayatullah G, Zhou H, Chang S, et al
    Tumor microenvironment characterization in cervical cancer identifies prognostic relevant gene signatures.
    PLoS One. 2021;16:e0249374.
    PubMed     Abstract available


  8. VIEIRA MA, de Araujo RLC, da Cunha Andrade CEM, Schmidt RL, et al
    A randomized clinical trial of a new anti-cervical stenosis device after conization by loop electrosurgical excision.
    PLoS One. 2021;16:e0242067.
    PubMed     Abstract available


  9. SONGANE M, Grossmann V
    The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value.
    PLoS One. 2021;16:e0244722.
    PubMed     Abstract available


  10. VALE DB, Silva MT, Discacciati MG, Polegatto I, et al
    Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country.
    PLoS One. 2021;16:e0251688.
    PubMed     Abstract available


  11. SUZUKI S, Hayata E, Hoshi SI, Sekizawa A, et al
    Current status of cervical cytology during pregnancy in Japan.
    PLoS One. 2021;16:e0245282.
    PubMed     Abstract available


  12. BADRE-ESFAHANI S, Petersen LK, Tatari CR, Blaakaer J, et al
    Perceptions of cervical cancer prevention among a group of ethnic minority women in Denmark-A qualitative study.
    PLoS One. 2021;16:e0250816.
    PubMed     Abstract available


  13. LIM YJ, Lee HN
    Optimal use of radiotherapy in the definitive treatment of non-bulky IB-IIA cervical cancer: A population-based long-term survival analysis.
    PLoS One. 2021;16:e0253649.
    PubMed     Abstract available


  14. KARAWEKPANYAWONG N, Kaewkitikul K, Maneeton B, Maneeton N, et al
    The prevalence of depressive disorder and its association in Thai cervical cancer patients.
    PLoS One. 2021;16:e0252779.
    PubMed     Abstract available


  15. LI Y, Kong Q, Wei H, Wang Y, et al
    Comparison of the complications between minimally invasive surgery and open surgical treatments for early-stage cervical cancer: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0253143.
    PubMed     Abstract available


  16. MOISE RK, Balise R, Ragin C, Kobetz E, et al
    Cervical cancer risk and access: Utilizing three statistical tools to assess Haitian women in South Florida.
    PLoS One. 2021;16:e0254089.
    PubMed     Abstract available


  17. BEYENE T, Akibu M, Bekele H, Seyoum W, et al
    Risk factors for precancerous cervical lesion among women screened for cervical cancer in south Ethiopia: Unmatched case-control study.
    PLoS One. 2021;16:e0254663.
    PubMed     Abstract available


  18. HOPKINS KL, Jaffer M, Hlongwane KE, Otwombe K, et al
    Assessing national cervical cancer screening guidelines: Results from an HIV testing clinic also screening for cervical cancer and HPV in Soweto, South Africa.
    PLoS One. 2021;16:e0255124.
    PubMed     Abstract available


  19. TERMRUNGRUANGLERT W, Khemapech N, Vasuratna A, Havanond P, et al
    The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand.
    PLoS One. 2021;16:e0245894.
    PubMed     Abstract available


  20. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease.
    PLoS One. 2021;16:e0249809.
    PubMed     Abstract available


  21. KEETILE M, Ndlovu K, Letamo G, Disang M, et al
    Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15-64 years in Botswana.
    PLoS One. 2021;16:e0255581.
    PubMed     Abstract available


  22. ST-MARTIN G, Viborg PH, Andersen ABT, Andersen B, et al
    Histological outcomes in HPV-screened elderly women in Denmark.
    PLoS One. 2021;16:e0246902.
    PubMed     Abstract available


  23. PONCET L, Panjo H, Ringa V, Andro A, et al
    Do vulnerable groups access prevention services? Cervical cancer screening and HIV testing among homeless migrant women in the Paris metropolitan area.
    PLoS One. 2021;16:e0255900.
    PubMed     Abstract available


  24. SUCHONSKA B, Gajzlerska-Majewska W, Wielgos M
    Evaluation of a real-time optoelectronic method in the diagnostics of CIN over four years of observations.
    PLoS One. 2021;16:e0247702.
    PubMed     Abstract available


  25. SUNDSTROM K, Lamin H, Dillner J
    Validation of the cobas 6800 human papillomavirus test in primary cervical screening.
    PLoS One. 2021;16:e0247291.
    PubMed     Abstract available


    January 2020
  26. GU Y, Wan C, Qiu J, Cui Y, et al
    Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis.
    PLoS One. 2020;15:e0224001.
    PubMed     Abstract available


  27. DE RYCKE Y, Tubach F, Lafourcade A, Guillo S, et al
    Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France.
    PLoS One. 2020;15:e0228660.
    PubMed     Abstract available


  28. MEIRA KC, Silva GWDS, Dos Santos J, Guimaraes RM, et al
    Analysis of the effects of the age-period-birth cohort on cervical cancer mortality in the Brazilian Northeast.
    PLoS One. 2020;15:e0226258.
    PubMed     Abstract available


  29. MIKI Y, Tase T, Tokunaga H, Yaegashi N, et al
    Cervical cancer screening rates before and after the Great East Japan Earthquake in the Miyagi Prefecture, Japan.
    PLoS One. 2020;15:e0229924.
    PubMed     Abstract available


  30. SETIAWAN D, Andrijono, Hadinegoro SR, Meyta H, et al
    Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
    PLoS One. 2020;15:e0230359.
    PubMed     Abstract available


  31. AYNALEM BY, Anteneh KT, Enyew MM
    Utilization of cervical cancer screening and associated factors among women in Debremarkos town, Amhara region, Northwest Ethiopia: Community based cross-sectional study.
    PLoS One. 2020;15:e0231307.
    PubMed     Abstract available


  32. SULTANA F, Roeske L, Malloy MJ, McDermott TL, et al
    Implementation of Australia's renewed cervical screening program: Preparedness of general practitioners and nurses.
    PLoS One. 2020;15:e0228042.
    PubMed     Abstract available


  33. DUAN L, Du H, Wang C, Huang X, et al
    The application of BMRT-HPV viral load to secondary screening strategies for cervical cancer.
    PLoS One. 2020;15:e0232117.
    PubMed     Abstract available


  34. AMPOFO AG, Adumatta AD, Owusu E, Awuviry-Newton K, et al
    A cross-sectional study of barriers to cervical cancer screening uptake in Ghana: An application of the health belief model.
    PLoS One. 2020;15:e0231459.
    PubMed     Abstract available


  35. ONGTENGCO N, Thiam H, Collins Z, De Jesus EL, et al
    Role of gender in perspectives of discrimination, stigma, and attitudes relative to cervical cancer in rural Senegal.
    PLoS One. 2020;15:e0232291.
    PubMed     Abstract available


  36. WU Q, Jia M, Chen H, Zhang S, et al
    The economic burden of cervical cancer from diagnosis to one year after final discharge in Henan Province, China: A retrospective case series study.
    PLoS One. 2020;15:e0232129.
    PubMed     Abstract available


  37. DUAN L, Du H, Wang C, Huang X, et al
    The effectiveness of HPV viral load, reflected by Cobas 4800 HPV-Ct values for the triage of HPV-positive women in primary cervical cancer screening: Direct endocervical samples.
    PLoS One. 2020;15:e0232107.
    PubMed     Abstract available


  38. SERMAN F, Favre J, Deken V, Guittet L, et al
    The association between cervical cancer screening participation and the deprivation index of the location of the family doctor's office.
    PLoS One. 2020;15:e0232814.
    PubMed     Abstract available


  39. LIMA MS, Brito EAC, Siqueira HFF, Santos MO, et al
    Trends in cervical cancer and its precursor forms to evaluate screening policies in a mid-sized Northeastern Brazilian city.
    PLoS One. 2020;15:e0233354.
    PubMed     Abstract available


  40. MBOUMBA BOUASSA RS, Pere H, Gubavu C, Prazuck T, et al
    Serum and cervicovaginal IgG immune responses against alpha7 and alpha9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.
    PLoS One. 2020;15:e0233084.
    PubMed     Abstract available


  41. CASTLE PE, Varallo JE, Bertram MM, Ratshaa B, et al
    High-risk human papillomavirus prevalence in self-collected cervicovaginal specimens from human immunodeficiency virus (HIV)-negative women and women living with HIV living in Botswana.
    PLoS One. 2020;15:e0229086.
    PubMed     Abstract available


  42. MIGUEL TP, Laurienzo CE, Faria EF, Sarri AJ, et al
    Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction.
    PLoS One. 2020;15:e0234389.
    PubMed     Abstract available


  43. FULLAR A, Karaszi K, Hollosi P, Lendvai G, et al
    Two ways of epigenetic silencing of TFPI2 in cervical cancer.
    PLoS One. 2020;15:e0234873.
    PubMed     Abstract available


  44. LAYMAN H, Rickert KW, Wilson S, Aksyuk AA, et al
    Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18.
    PLoS One. 2020;15:e0229672.
    PubMed     Abstract available


  45. HAO S, Wang C, Liu S, He J, et al
    HPV genotypic spectrum in Jilin province, China, where non-vaccine-covered HPV53 and 51 are prevalent, exhibits a bimodal age-specific pattern.
    PLoS One. 2020;15:e0230640.
    PubMed     Abstract available


  46. COSTA AS, Gomes JM, Germani ACCG, da Silva MR, et al
    Knowledge gaps and acquisition about HPV and its vaccine among Brazilian medical students.
    PLoS One. 2020;15:e0230058.
    PubMed     Abstract available


  47. LILLIECREUTZ C, Karlsson H, Spetz Holm AC
    Participation in interventions and recommended follow-up for non-attendees in cervical cancer screening -taking the women's own preferred test method into account-A Swedish randomised controlled trial.
    PLoS One. 2020;15:e0235202.
    PubMed     Abstract available


  48. RAINES MILENKOV A, Felini M, Baker E, Acharya R, et al
    Uptake of cancer screenings among a multiethnic refugee population in North Texas, 2014-2018.
    PLoS One. 2020;15:e0230675.
    PubMed     Abstract available


  49. HAILU HE, Mondul AM, Rozek LS, Geleta T, et al
    Descriptive Epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia.
    PLoS One. 2020;15:e0230625.
    PubMed     Abstract available


  50. MA Y, Di J, Bi H, Zhao Q, et al
    Comparison of the detection rate of cervical lesion with TruScreen, LBC test and HPV test: A Real-world study based on population screening of cervical cancer in rural areas of China.
    PLoS One. 2020;15:e0233986.
    PubMed     Abstract available


  51. PEREZ-QUINTANILLA M, Mendez-Martinez R, Vazquez-Vega S, Espinosa-Romero R, et al
    High prevalence of human papillomavirus and European variants of HPV 16 infecting concomitantly to cervix and oral cavity in HIV positive women.
    PLoS One. 2020;15:e0227900.
    PubMed     Abstract available


  52. PAGE CM, Ibrahim S, Park LP, Huchko MJ, et al
    Systems-level barriers to treatment in a cervical cancer prevention program in Kenya: Several observational studies.
    PLoS One. 2020;15:e0235264.
    PubMed     Abstract available


  53. CHAPARRO RM, Rodriguez B, Maza Y, Moyano D, et al
    Factors associated with hindering the acceptance of HPV vaccination among caregivers - A cross-sectional study in Argentina.
    PLoS One. 2020;15:e0229793.
    PubMed     Abstract available


  54. KIM H, Lim YK, Goh Y, Jeong C, et al
    Plan optimization with L0-norm and group sparsity constraints for a new rotational, intensity-modulated brachytherapy for cervical cancer.
    PLoS One. 2020;15:e0236585.
    PubMed     Abstract available


  55. HALL MT, Smith MA, Simms KT, Barnabas RV, et al
    The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study.
    PLoS One. 2020;15:e0231388.
    PubMed     Abstract available


  56. OLIVEIRA CM, Musselwhite LW, de Paula Pantano N, Vazquez FL, et al
    Detection of HPV E6 oncoprotein from urine via a novel immunochromatographic assay.
    PLoS One. 2020;15:e0232105.
    PubMed     Abstract available


  57. QIAN C, Liu H, Feng Y, Meng S, et al
    Clinical characteristics and risk of second primary lung cancer after cervical cancer: A population-based study.
    PLoS One. 2020;15:e0231807.
    PubMed     Abstract available


  58. CHE D, Yang Z, Wei H, Wang X, et al
    The Adler grade by Doppler ultrasound is associated with clinical pathology of cervical cancer: Implication for clinical management.
    PLoS One. 2020;15:e0236725.
    PubMed     Abstract available


  59. NGUNE I, Kalembo F, Loessl B, Kivuti-Bitok LW, et al
    Biopsychosocial risk factors and knowledge of cervical cancer among young women: A case study from Kenya to inform HPV prevention in Sub-Saharan Africa.
    PLoS One. 2020;15:e0237745.
    PubMed     Abstract available


  60. IBANEZ R, Roura E, Monfil L, Rodriguez LA, et al
    Long-term protection of HPV test in women at risk of cervical cancer.
    PLoS One. 2020;15:e0237988.
    PubMed     Abstract available


  61. ARRIVILLAGA M, Bermudez PC, Garcia-Cifuentes JP, Botero J, et al
    Innovative prototypes for cervical cancer prevention in low-income primary care settings: A human-centered design approach.
    PLoS One. 2020;15:e0238099.
    PubMed     Abstract available


  62. WEEGAR R, Sundstrom K
    Using machine learning for predicting cervical cancer from Swedish electronic health records by mining hierarchical representations.
    PLoS One. 2020;15:e0237911.
    PubMed     Abstract available


  63. HILLMAN RT, Cardnell R, Fujimoto J, Lee WC, et al
    Comparative genomics of high grade neuroendocrine carcinoma of the cervix.
    PLoS One. 2020;15:e0234505.
    PubMed     Abstract available


  64. BUTLER TL, Anderson K, Condon JR, Garvey G, et al
    Indigenous Australian women's experiences of participation in cervical screening.
    PLoS One. 2020;15:e0234536.
    PubMed     Abstract available


  65. SONG F, Du H, Wang C, Huang X, et al
    The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    PLoS One. 2020;15:e0234518.
    PubMed     Abstract available


  66. CHAUHAN AS, Prinja S, Srinivasan R, Rai B, et al
    Cost effectiveness of strategies for cervical cancer prevention in India.
    PLoS One. 2020;15:e0238291.
    PubMed     Abstract available


  67. ENDALEW DA, Moti D, Mohammed N, Redi S, et al
    Knowledge and practice of cervical cancer screening and associated factors among reproductive age group women in districts of Gurage zone, Southern Ethiopia. A cross-sectional study.
    PLoS One. 2020;15:e0238869.
    PubMed     Abstract available


  68. FOGELBERG S, Clements MS, Pedersen K, Sy S, et al
    Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden.
    PLoS One. 2020;15:e0239611.
    PubMed     Abstract available


  69. KHAN MA, Tiwari D, Dongre A, Sadaf, et al
    Exploring the p53 connection of cervical cancer pathogenesis involving north-east Indian patients.
    PLoS One. 2020;15:e0238500.
    PubMed     Abstract available


  70. GUO A, Drake BF, Khan YM, Langabeer Ii JR, et al
    Time-series cardiovascular risk factors and receipt of screening for breast, cervical, and colon cancer: The Guideline Advantage.
    PLoS One. 2020;15:e0236836.
    PubMed     Abstract available


  71. ABU SH, Woldehanna BT, Nida ET, Tilahun AW, et al
    The role of health education on cervical cancer screening uptake at selected health centers in Addis Ababa.
    PLoS One. 2020;15:e0239580.
    PubMed     Abstract available


  72. MOODLEY J, Constant D, Mwaka AD, Scott SE, et al
    Mapping awareness of breast and cervical cancer risk factors, symptoms and lay beliefs in Uganda and South Africa.
    PLoS One. 2020;15:e0240788.
    PubMed     Abstract available


  73. SHRESTHA G, Mulmi R, Phuyal P, Thakur RK, et al
    Experiences of cervical cancer survivors in Chitwan, Nepal: A qualitative study.
    PLoS One. 2020;15:e0234834.
    PubMed     Abstract available


  74. WOLLANCHO W, Amdissa D, Bamboro S, Wasihun Y, et al
    Determining behavioral intention and its predictors towards cervical cancer screening among women in Gomma district, Jimma, Ethiopia: Application of the theory of planned behavior.
    PLoS One. 2020;15:e0238472.
    PubMed     Abstract available



  75. Correction: Long-term protection of HPV test in women at risk of cervical cancer.
    PLoS One. 2020;15:e0243000.
    PubMed     Abstract available


  76. ISABIRYE A, Mbonye MK, Kwagala B
    Predictors of cervical cancer screening uptake in two districts of Central Uganda.
    PLoS One. 2020;15:e0243281.
    PubMed     Abstract available


  77. MEGERSA BS, Bussmann H, Barnighausen T, Muche AA, et al
    Community cervical cancer screening: Barriers to successful home-based HPV self-sampling in Dabat district, North Gondar, Ethiopia. A qualitative study.
    PLoS One. 2020;15:e0243036.
    PubMed     Abstract available


  78. KASSIE AM, Abate BB, Kassaw MW, Aragie TG, et al
    Impact of knowledge and attitude on the utilization rate of cervical cancer screening tests among Ethiopian women: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0239927.
    PubMed     Abstract available


  79. KATO M, Onoyama I, Kawakami M, Yoshida S, et al
    Downregulation of 5-hydroxymethylcytosine is associated with the progression of cervical intraepithelial neoplasia.
    PLoS One. 2020;15:e0241482.
    PubMed     Abstract available


  80. TOUNKARA FK, Teguete I, Guedou FA, Goma-Matsetse E, et al
    Human papillomavirus genotype distribution and factors associated among female sex workers in West Africa.
    PLoS One. 2020;15:e0242711.
    PubMed     Abstract available


  81. TAKU O, Meiring TL, Gustavsson I, Phohlo K, et al
    Acceptability of self- collection for human papillomavirus detection in the Eastern Cape, South Africa.
    PLoS One. 2020;15:e0241781.
    PubMed     Abstract available


  82. TOYODA Y, Tabuchi T, Hama H, Morishima T, et al
    Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: Stomach, colorectum, lung, breast and cervix.
    PLoS One. 2020;15:e0244644.
    PubMed     Abstract available


    January 2019
  83. MACHIDA H, Matsuo K, Furusawa A, Kita T, et al
    Profile of treatment-related complications in women with clinical stage IB-IIB cervical cancer: A nationwide cohort study in Japan.
    PLoS One. 2019;14:e0210125.
    PubMed     Abstract available


  84. BASTA T, Knapp P, Blecharz P, Bodnar L, et al
    Current management of cervical cancer in Poland-Analysis of the questionnaire trial for the years 2002-2014 in relation to ASCO 2016 recommendations.
    PLoS One. 2019;14:e0209901.
    PubMed     Abstract available


  85. LE GM, Radcliffe K, Lyles C, Lyson HC, et al
    Perceptions of cervical cancer prevention on Twitter uncovered by different sampling strategies.
    PLoS One. 2019;14:e0211931.
    PubMed     Abstract available


  86. SILVEIRA CRF, Cipelli M, Manzine C, Rabelo-Santos SH, et al
    Swainsonine, an alpha-mannosidase inhibitor, may worsen cervical cancer progression through the increase in myeloid derived suppressor cells population.
    PLoS One. 2019;14:e0213184.
    PubMed     Abstract available


  87. TEAME H, Gebremariam L, Kahsay T, Berhe K, et al
    Factors affecting utilization of cervical cancer screening services among women attending public hospitals in Tigray region, Ethiopia, 2018; Case control study.
    PLoS One. 2019;14:e0213546.
    PubMed     Abstract available


  88. PANKAKOSKI M, Anttila A, Sarkeala T, Heinavaara S, et al
    Effectiveness of cervical cancer screening at age 65 - A register-based cohort study.
    PLoS One. 2019;14:e0214486.
    PubMed     Abstract available


  89. LI T, Zhou W, Li Y, Gan Y, et al
    MiR-4524b-5p/WTX/beta-catenin axis functions as a regulator of metastasis in cervical cancer.
    PLoS One. 2019;14:e0214822.
    PubMed     Abstract available


  90. LIN CK, Liu ST, Chang CC, Huang SM, et al
    Regulatory mechanisms of fluvastatin and lovastatin for the p21 induction in human cervical cancer HeLa cells.
    PLoS One. 2019;14:e0214408.
    PubMed     Abstract available


  91. PARK S, Lee S, Kim J, Kim G, et al
    DeltaNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.
    PLoS One. 2019;14:e0214867.
    PubMed     Abstract available


  92. CAMPOS RG, Malacara Rosas A, Gutierrez Santillan E, Delgado Gutierrez M, et al
    Unusual prevalence of high-risk genotypes of human papillomavirus in a group of women with neoplastic lesions and cervical cancer from Central Mexico.
    PLoS One. 2019;14:e0215222.
    PubMed     Abstract available


  93. WANG W, Liu X, Meng Q, Zhang F, et al
    Nomograms predicting survival and patterns of failure in patients with cervical cancer treated with concurrent chemoradiotherapy: A special focus on lymph nodes metastases.
    PLoS One. 2019;14:e0214498.
    PubMed     Abstract available


  94. TAREKEGN AA, Mengistu MY, Mirach TH
    Health professionals' willingness to pay and associated factors for cervical cancer screening program at College of Medicine and Health Sciences, University of Gondar, Northwest Ethiopia.
    PLoS One. 2019;14:e0215904.
    PubMed     Abstract available


  95. GETACHEW S, Getachew E, Gizaw M, Ayele W, et al
    Cervical cancer screening knowledge and barriers among women in Addis Ababa, Ethiopia.
    PLoS One. 2019;14:e0216522.
    PubMed     Abstract available


  96. PARK S, Lee S, Kim J, Kim G, et al
    Correction: DeltaNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.
    PLoS One. 2019;14:e0216968.
    PubMed     Abstract available


  97. KIM HW, Kim DH, Kim YH, Lee EJ, et al
    Clinical nurses' awareness and caring experiences for patients with cervical cancer: A qualitative study.
    PLoS One. 2019;14:e0217201.
    PubMed     Abstract available


  98. VODICKA EL, Chung MH, Zimmermann MR, Kosgei RJ, et al
    Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya.
    PLoS One. 2019;14:e0217331.
    PubMed     Abstract available


  99. BERGENGREN L, Lillsunde-Larsson G, Helenius G, Karlsson MG, et al
    HPV-based screening for cervical cancer among women 55-59 years of age.
    PLoS One. 2019;14:e0217108.
    PubMed     Abstract available


  100. MINNAAR CA, Kotzen JA, Ayeni OA, Naidoo T, et al
    The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial.
    PLoS One. 2019;14:e0217894.
    PubMed     Abstract available


  101. KRINGS A, Dunyo P, Pesic A, Tetteh S, et al
    Characterization of Human Papillomavirus prevalence and risk factors to guide cervical cancer screening in the North Tongu District, Ghana.
    PLoS One. 2019;14:e0218762.
    PubMed     Abstract available


  102. ALLANSON ER, Powell A, Bulsara M, Lee HL, et al
    Morbidity after surgical management of cervical cancer in low and middle income countries: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0217775.
    PubMed     Abstract available


  103. WEBB S, Kelly PJ, Wickliffe J, Ault K, et al
    Validating self-reported cervical cancer screening among women leaving jails.
    PLoS One. 2019;14:e0219178.
    PubMed     Abstract available


  104. YU W, Kou C, Bai W, Yu X, et al
    The diagnostic performance of PET/CT scans for the detection of para-aortic metastatic lymph nodes in patients with cervical cancer: A meta-analysis.
    PLoS One. 2019;14:e0220080.
    PubMed     Abstract available


  105. YANG WT, Zhao ZX, Li B, Zheng PS, et al
    NF-YA transcriptionally activates the expression of SOX2 in cervical cancer stem cells.
    PLoS One. 2019;14:e0215494.
    PubMed     Abstract available


  106. MOODLEY J, Scott SE, Mwaka AD, Constant D, et al
    Development and validation of the African Women Awareness of CANcer (AWACAN) tool for breast and cervical cancer.
    PLoS One. 2019;14:e0220545.
    PubMed     Abstract available


  107. BENSKI AC, Viviano M, Jinoro J, Alec M, et al
    HPV self-testing for primary cervical cancer screening in Madagascar: VIA/VILI triage compliance in HPV-positive women.
    PLoS One. 2019;14:e0220632.
    PubMed     Abstract available


  108. CHEN CP, Kung PT, Wang YH, Tsai WC, et al
    Effect of time interval from diagnosis to treatment for cervical cancer on survival: A nationwide cohort study.
    PLoS One. 2019;14:e0221946.
    PubMed     Abstract available


  109. DREYER G, Maske C, Stander M
    Clinical evaluation and budget impact analysis of cervical cancer screening using cobas 4800 HPV screening technology in the public sector of South Africa.
    PLoS One. 2019;14:e0221495.
    PubMed     Abstract available


  110. PAGE CM, Ibrahim S, Park LP, Huchko MJ, et al
    Patient factors affecting successful linkage to treatment in a cervical cancer prevention program in Kenya: A prospective cohort study.
    PLoS One. 2019;14:e0222750.
    PubMed     Abstract available


  111. LIU YJ, Keane A, Simms KT, Lew JB, et al
    Development and application of a framework to estimate health care costs in China: The cervical cancer example.
    PLoS One. 2019;14:e0222760.
    PubMed     Abstract available


  112. MAHUMUD RA, Alam K, Dunn J, Gow J, et al
    The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
    PLoS One. 2019;14:e0223658.
    PubMed     Abstract available



  113. Retraction: MiR-375 Is Epigenetically Downregulated by HPV-16 E6 Mediated DNMT1 Upregulation and Modulates EMT of Cervical Cancer Cells by Suppressing lncRNA MALAT1.
    PLoS One. 2019;14:e0224167.
    PubMed    


  114. JIANG L, Tian X, Peng D, Zhang L, et al
    HPV prevalence and genotype distribution among women in Shandong Province, China: Analysis of 94,489 HPV genotyping results from Shandong's largest independent pathology laboratory.
    PLoS One. 2019;14:e0210311.
    PubMed     Abstract available


  115. DANKAI W, Khunamornpong S, Siriaunkgul S, Soongkhaw A, et al
    Role of genomic DNA methylation in detection of cytologic and histologic abnormalities in high risk HPV-infected women.
    PLoS One. 2019;14:e0210289.
    PubMed     Abstract available


  116. BAASLAND I, Romundstad PR, Eide ML, Jonassen CM, et al
    Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
    PLoS One. 2019;14:e0210997.
    PubMed     Abstract available


  117. HANSEN MB, Tietze A, Haack S, Kallehauge J, et al
    Robust estimation of hemo-dynamic parameters in traditional DCE-MRI models.
    PLoS One. 2019;14:e0209891.
    PubMed     Abstract available


  118. ZOU W, Han Y, Zhang Y, Hu C, et al
    Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0225264.
    PubMed     Abstract available


  119. SALEEM A, Bekele A, Fitzpatrick MB, Mahmoud EA, et al
    Knowledge and awareness of cervical cancer in Southwestern Ethiopia is lacking: A descriptive analysis.
    PLoS One. 2019;14:e0215117.
    PubMed     Abstract available


  120. GRANT BD, Quang T, Possati-Resende JC, Scapulatempo-Neto C, et al
    A mobile-phone based high-resolution microendoscope to image cervical precancer.
    PLoS One. 2019;14:e0211045.
    PubMed     Abstract available


  121. BINKA C, Doku DT, Nyarko SH, Awusabo-Asare K, et al
    Male support for cervical cancer screening and treatment in rural Ghana.
    PLoS One. 2019;14:e0224692.
    PubMed     Abstract available


  122. SKROUMPELOS A, Agorastos T, Constantinidis T, Chatzistamatiou K, et al
    Economic evaluation of HPV DNA test as primary screening method for cervical cancer: A health policy discussion in Greece.
    PLoS One. 2019;14:e0226335.
    PubMed     Abstract available


  123. MENON S, Rossi R, Kariisa M, Acharya SD, et al
    Relationship between Highly Active Antiretroviral Therapy (HAART) and human papillomavirus type 16 (HPV 16) infection among women in Sub-Saharan Africa and public health implications: A systematic review.
    PLoS One. 2019;14:e0213086.
    PubMed     Abstract available


  124. LI T, Zhou W, Li Y, Gan Y, et al
    Correction: MiR-4524b-5p/WTX/beta-catenin axis functions as a regulator of metastasis in cervical cancer.
    PLoS One. 2019;14:e0226864.
    PubMed     Abstract available


  125. LAWAL IO, Lengana T, Janse van Rensburg C, Reyneke F, et al
    Fluorodeoxyglucose Positron Emission Tomography integrated with computed tomography in carcinoma of the cervix: Its impact on accurate staging and the predictive role of its metabolic parameters.
    PLoS One. 2019;14:e0215412.
    PubMed     Abstract available


  126. COHEN O, Schejter E, Agizim R, Schonman R, et al
    Postcoital bleeding is a predictor for cervical dysplasia.
    PLoS One. 2019;14:e0217396.
    PubMed     Abstract available


  127. NDIZEYE Z, Vanden Broeck D, Lebelo RL, Bogers J, et al
    Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control.
    PLoS One. 2019;14:e0209303.
    PubMed     Abstract available


  128. ILIC I, Babic G, Dimitrijevic A, Ilic M, et al
    Psychological distress among women with abnormal pap smear results in Serbia: Validity and reliability of the Cervical Dysplasia Distress Questionnaire.
    PLoS One. 2019;14:e0218070.
    PubMed     Abstract available


  129. KASAMATSU E, Rodriguez Riveros MI, Soilan AM, Ortega M, et al
    Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: A population-based study in Paraguay.
    PLoS One. 2019;14:e0218016.
    PubMed     Abstract available


  130. KIM J, Jun SY
    Analytic performance of PANArray HPV and HPV 9G DNA chip tests for genotyping of high-risk human papillomavirus in cervical ThinPrep PreservCyt samples.
    PLoS One. 2019;14:e0224483.
    PubMed     Abstract available


  131. HUANG J, Luo JY, Tan HZ
    Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis.
    PLoS One. 2019;14:e0222772.
    PubMed     Abstract available


  132. SHUKLA S, Jadli M, Thakur K, Shishodia G, et al
    Level of phospho-STAT3 (Tyr705) correlates with copy number and physical state of human papillomavirus 16 genome in cervical precancer and cancer lesions.
    PLoS One. 2019;14:e0222089.
    PubMed     Abstract available


  133. OMORI M, Kondo T, Tagaya H, Watanabe Y, et al
    Utility of imaging modalities for predicting carcinogenesis in lobular endocervical glandular hyperplasia.
    PLoS One. 2019;14:e0221088.
    PubMed     Abstract available


  134. JAWOREK H, Kubanova K, Koudelakova V, Slavkovsky R, et al
    Pitfalls of commercially available HPV tests in HPV68a detection.
    PLoS One. 2019;14:e0220373.
    PubMed     Abstract available


  135. TAYYAR Y, Shiels R, Bulmer AC, Lam AK, et al
    Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237.
    PLoS One. 2019;14:e0225774.
    PubMed     Abstract available


  136. WESTRE B, Giske A, Guttormsen H, Wergeland Sorbye S, et al
    Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.
    PLoS One. 2019;14:e0221546.
    PubMed     Abstract available


  137. RAI SN, Srivastava S, Pan J, Wu X, et al
    Multi-group diagnostic classification of high-dimensional data using differential scanning calorimetry plasma thermograms.
    PLoS One. 2019;14:e0220765.
    PubMed     Abstract available


  138. NEJO YT, Olaleye DO, Odaibo GN
    Molecular characterisation of genital human papillomavirus among women in Southwestern, Nigeria.
    PLoS One. 2019;14:e0224748.
    PubMed     Abstract available


    January 2018
  139. BADANO I, Sanabria DJ, Totaro ME, Rubinstein S, et al
    Mitochondrial DNA ancestry, HPV infection and the risk of cervical cancer in a multiethnic population of northeastern Argentina.
    PLoS One. 2018;13:e0190966.
    PubMed     Abstract available


  140. TEAME H, Addissie A, Ayele W, Hirpa S, et al
    Factors associated with cervical precancerous lesions among women screened for cervical cancer in Addis Ababa, Ethiopia: A case control study.
    PLoS One. 2018;13:e0191506.
    PubMed     Abstract available


  141. SHIM SH, Lim MC, Kim HJ, Lee M, et al
    Can simple trachelectomy or conization show comparable survival rate compared with radical trachelectomy in IA1 cervical cancer patients with lymphovascular space invasion who wish to save fertility? A systematic review and guideline recommendation.
    PLoS One. 2018;13:e0189847.
    PubMed     Abstract available


  142. JAUDAN A, Sharma S, Malek SNA, Dixit A, et al
    Induction of apoptosis by pinostrobin in human cervical cancer cells: Possible mechanism of action.
    PLoS One. 2018;13:e0191523.
    PubMed     Abstract available


  143. MARKT SC, Tang T, Cronin AM, Katz IT, et al
    Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival.
    PLoS One. 2018;13:e0193047.
    PubMed     Abstract available


  144. HALL MT, Simms KT, Lew JB, Smith MA, et al
    Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.
    PLoS One. 2018;13:e0185332.
    PubMed     Abstract available


  145. LAM CT, Mueller J, Asma B, Asiedu M, et al
    An integrated strategy for improving contrast, durability, and portability of a Pocket Colposcope for cervical cancer screening and diagnosis.
    PLoS One. 2018;13:e0192530.
    PubMed     Abstract available


  146. BROBERG G, Wang J, Ostberg AL, Adolfsson A, et al
    Socio-economic and demographic determinants affecting participation in the Swedish cervical screening program: A population-based case-control study.
    PLoS One. 2018;13:e0190171.
    PubMed     Abstract available


  147. LANG KUHS KA, Lin SW, Hua X, Schiffman M, et al
    T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study.
    PLoS One. 2018;13:e0178167.
    PubMed     Abstract available


  148. SHEIKHZADEH F, Ward RK, van Niekerk D, Guillaud M, et al
    Automatic labeling of molecular biomarkers of immunohistochemistry images using fully convolutional networks.
    PLoS One. 2018;13:e0190783.
    PubMed     Abstract available


  149. PALATNIK A, Ye S, Kendziorski C, Iden M, et al
    Correction: Identification of a serum-induced transcriptional signature associated with metastatic cervical cancer.
    PLoS One. 2018;13:e0193687.
    PubMed     Abstract available


  150. WANG W, Yue Z, Tian Z, Xie Y, et al
    Expression of Yin Yang 1 in cervical cancer and its correlation with E-cadherin expression and HPV16 E6.
    PLoS One. 2018;13:e0193340.
    PubMed     Abstract available


  151. LI XM, Liu J, Pan FF, Shi DD, et al
    Quercetin and aconitine synergistically induces the human cervical carcinoma HeLa cell apoptosis via endoplasmic reticulum (ER) stress pathway.
    PLoS One. 2018;13:e0191062.
    PubMed     Abstract available


  152. MIRI MR, Moodi M, Sharif-Zadeh GR, Malaki Moghadam H, et al
    Cognitive predictors of cervical cancer screening's stages of change among sample of Iranian women health volunteers: A path analysis.
    PLoS One. 2018;13:e0193638.
    PubMed     Abstract available


  153. JIN YM, Liu SS, Chen J, Chen YN, et al
    Robotic radical hysterectomy is superior to laparoscopic radical hysterectomy and open radical hysterectomy in the treatment of cervical cancer.
    PLoS One. 2018;13:e0193033.
    PubMed     Abstract available


  154. YANG Y, Moser MAJ, Zhang E, Zhang W, et al
    Development of a statistical model for cervical cancer cell death with irreversible electroporation in vitro.
    PLoS One. 2018;13:e0195561.
    PubMed     Abstract available


  155. DIAZ A, Baade PD, Valery PC, Whop LJ, et al
    Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012).
    PLoS One. 2018;13:e0196764.
    PubMed     Abstract available


  156. LIU S, Minaguchi T, Lachkar B, Zhang S, et al
    Separate analysis of human papillomavirus E6 and E7 messenger RNAs to predict cervical neoplasia progression.
    PLoS One. 2018;13:e0193061.
    PubMed     Abstract available


  157. GRANDAHL M, Chun Paek S, Grisurapong S, Sherer P, et al
    Parents' knowledge, beliefs, and acceptance of the HPV vaccination in relation to their socio-demographics and religious beliefs: A cross-sectional study in Thailand.
    PLoS One. 2018;13:e0193054.
    PubMed     Abstract available


  158. REISNER SL, Deutsch MB, Peitzmeier SM, White Hughto JM, et al
    Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients.
    PLoS One. 2018;13:e0190172.
    PubMed     Abstract available


  159. KELLY PJ, Allison M, Ramaswamy M
    Cervical cancer screening among incarcerated women.
    PLoS One. 2018;13:e0199220.
    PubMed     Abstract available


  160. YUEN WWY, Lee A, Chan PKS, Tran L, et al
    Uptake of human papillomavirus (HPV) vaccination in Hong Kong: Facilitators and barriers among adolescent girls and their parents.
    PLoS One. 2018;13:e0194159.
    PubMed     Abstract available


  161. ZHANG Q, Xiong Y, Ye J, Zhang L, et al
    Influence of clinicopathological characteristics and comprehensive treatment models on the prognosis of small cell carcinoma of the cervix: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0192784.
    PubMed     Abstract available


  162. KORI M, Yalcin Arga K
    Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective.
    PLoS One. 2018;13:e0200717.
    PubMed     Abstract available


  163. ZAFRA-TANAKA JH, Hurtado-Villanueva ME, Saenz-Naranjo MDP, Taype-Rondan A, et al
    Self-perceived competence in early diagnosis of cervical cancer among recently graduated physicians from Lima, Peru.
    PLoS One. 2018;13:e0203778.
    PubMed     Abstract available


  164. BALOGUN F, Omotade O
    "She must have been sleeping around"...: Contextual interpretations of cervical cancer and views regarding HPV vaccination for adolescents in selected communities in Ibadan, Nigeria.
    PLoS One. 2018;13:e0203950.
    PubMed     Abstract available


  165. WEN YF, Cheng TT, Chen XL, Huang WJ, et al
    Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy.
    PLoS One. 2018;13:e0204334.
    PubMed     Abstract available


  166. LARMOUR LI, Cousins FL, Teague JA, Deane JA, et al
    A patient derived xenograft model of cervical cancer and cervical dysplasia.
    PLoS One. 2018;13:e0206539.
    PubMed     Abstract available


  167. MATENGE TG, Mash B
    Barriers to accessing cervical cancer screening among HIV positive women in Kgatleng district, Botswana: A qualitative study.
    PLoS One. 2018;13:e0205425.
    PubMed     Abstract available


  168. WONGJAMPA W, Ekalaksananan T, Chopjitt P, Chuerduangphui J, et al
    Suppression of miR-22, a tumor suppressor in cervical cancer, by human papillomavirus 16 E6 via a p53/miR-22/HDAC6 pathway.
    PLoS One. 2018;13:e0206644.
    PubMed     Abstract available


  169. DARENG EO, Olaniyan Y, Odutola MK, Adebamowo SN, et al
    Secular trend in interobserver agreement of VIA diagnosis for cervical cancer screening in Nigeria.
    PLoS One. 2018;13:e0208531.
    PubMed     Abstract available


  170. HORTLUND M, Elfstrom KM, Sparen P, Almstedt P, et al
    Cervical cancer screening in Sweden 2014-2016.
    PLoS One. 2018;13:e0209003.
    PubMed     Abstract available


  171. DENG H, Hillpot E, Yeboah P, Mondal S, et al
    Susceptibility of epithelial cells cultured from different regions of human cervix to HPV16-induced immortalization.
    PLoS One. 2018;13:e0199761.
    PubMed     Abstract available


  172. ROSSETTI RAM, Lorenzi NPC, Yokochi K, Rosa MBSF, et al
    B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses.
    PLoS One. 2018;13:e0199034.
    PubMed     Abstract available


  173. BERTAUT A, Coudert J, Bengrine L, Dancourt V, et al
    Does mammogram attendance influence participation in cervical and colorectal cancer screening? A prospective study among 1856 French women.
    PLoS One. 2018;13:e0198939.
    PubMed     Abstract available


  174. TORRES KL, Marino JM, Pires Rocha DA, de Mello MB, et al
    Self-sampling coupled to the detection of HPV 16 and 18 E6 protein: A promising option for detection of cervical malignancies in remote areas.
    PLoS One. 2018;13:e0201262.
    PubMed     Abstract available


  175. LECONTE BA, Szaniszlo P, Fennewald SM, Lou DI, et al
    Differences in the viral genome between HPV-positive cervical and oropharyngeal cancer.
    PLoS One. 2018;13:e0203403.
    PubMed     Abstract available


  176. HSU HC, Tai YJ, Chen YL, Chiang YC, et al
    Factors predicting parametrial invasion in patients with early-stage cervical carcinomas.
    PLoS One. 2018;13:e0204950.
    PubMed     Abstract available


  177. ABBAS-AGHABABAZADEH F, Li Q, Fridley BL
    Comparison of normalization approaches for gene expression studies completed with high-throughput sequencing.
    PLoS One. 2018;13:e0206312.
    PubMed     Abstract available


  178. EBISCH RMF, Ketelaars PJW, van der Sanden WMH, Schmeink CE, et al
    Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study.
    PLoS One. 2018;13:e0206219.
    PubMed     Abstract available


  179. SHERMAN SM, Bartholomew K, Denison HJ, Patel H, et al
    Knowledge, attitudes and awareness of the human papillomavirus among health professionals in New Zealand.
    PLoS One. 2018;13:e0197648.
    PubMed     Abstract available


  180. LINDSTROM AK, Hermansson RS, Gustavsson I, Hedlund Lindberg J, et al
    Cervical dysplasia in elderly women performing repeated self-sampling for HPV testing.
    PLoS One. 2018;13:e0207714.
    PubMed     Abstract available


  181. MCSHERRY LA, O'Leary E, Dombrowski SU, Francis JJ, et al
    Which primary care practitioners have poor human papillomavirus (HPV) knowledge? A step towards informing the development of professional education initiatives.
    PLoS One. 2018;13:e0208482.
    PubMed     Abstract available


    January 2017
  182. WEINMANN S, Naleway A, Swamy G, Krishnarajah G, et al
    Pregnancy Outcomes after Treatment for Cervical Cancer Precursor Lesions: An Observational Study.
    PLoS One. 2017;12:e0165276.
    PubMed     Abstract available


  183. ACERA A, Manresa JM, Rodriguez D, Rodriguez A, et al
    Increasing Cervical Cancer Screening Coverage: A Randomised, Community-Based Clinical Trial.
    PLoS One. 2017;12:e0170371.
    PubMed     Abstract available


  184. RAIFU AO, El-Zein M, Sangwa-Lugoma G, Ramanakumar A, et al
    Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) Performed by Nurse and Physician.
    PLoS One. 2017;12:e0170631.
    PubMed     Abstract available



  185. Correction: Pregnancy Outcomes after Treatment for Cervical Cancer Precursor Lesions: An Observational Study.
    PLoS One. 2017;12:e0172417.
    PubMed     Abstract available


  186. TEGUETE I, Dolo A, Sangare K, Sissoko A, et al
    Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali.
    PLoS One. 2017;12:e0172661.
    PubMed     Abstract available


  187. YOO W, Kim S, Huh WK, Dilley S, et al
    Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States.
    PLoS One. 2017;12:e0172548.
    PubMed     Abstract available


  188. GAO Q, Lin S, Bai P, Du M, et al
    FZUImageReg: A toolbox for medical image registration and dose fusion in cervical cancer radiotherapy.
    PLoS One. 2017;12:e0174926.
    PubMed     Abstract available


  189. LABEIT AM, Peinemann F
    Determinants of a GP visit and cervical cancer screening examination in Great Britain.
    PLoS One. 2017;12:e0174363.
    PubMed     Abstract available


  190. NAWALE L, Dubey P, Chaudhari B, Sarkar D, et al
    Anti-proliferative effect of novel primary cetyl alcohol derived sophorolipids against human cervical cancer cells HeLa.
    PLoS One. 2017;12:e0174241.
    PubMed     Abstract available


  191. CHANG C, Hsieh MK, Chang WY, Chiang AJ, et al
    Determining the optimal number and location of cutoff points with application to data of cervical cancer.
    PLoS One. 2017;12:e0176231.
    PubMed     Abstract available


  192. WANG L, Shen H, Feng B, Zhu D, et al
    Reduction in the copy number and expression level of the recurrent human papillomavirus integration gene fragile histidine triad (FHIT) predicts the transition of cervical lesions.
    PLoS One. 2017;12:e0175520.
    PubMed     Abstract available


  193. CHEN M, Zhang Y, Zheng PS
    Tafazzin (TAZ) promotes the tumorigenicity of cervical cancer cells and inhibits apoptosis.
    PLoS One. 2017;12:e0177171.
    PubMed     Abstract available


  194. MCKAY J, Tenet V, Franceschi S, Chabrier A, et al
    Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study.
    PLoS One. 2017;12:e0177775.
    PubMed     Abstract available


  195. ASIEDU MN, Agudogo J, Krieger MS, Miros R, et al
    Design and preliminary analysis of a vaginal inserter for speculum-free cervical cancer screening.
    PLoS One. 2017;12:e0177782.
    PubMed     Abstract available


  196. MCKAY J, Tenet V, Franceschi S, Chabrier A, et al
    Correction: Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study.
    PLoS One. 2017;12:e0181285.
    PubMed     Abstract available


  197. SANO H, Goto R, Hamashima C
    Does lack of resources impair access to breast and cervical cancer screening in Japan?
    PLoS One. 2017;12:e0180819.
    PubMed     Abstract available


  198. CABRERA-BECERRIL A, Vargas-De-Leon C, Hernandez S, Miramontes P, et al
    Modeling the dynamics of chromosomal alteration progression in cervical cancer: A computational model.
    PLoS One. 2017;12:e0180882.
    PubMed     Abstract available


  199. AWEKE YH, Ayanto SY, Ersado TL
    Knowledge, attitude and practice for cervical cancer prevention and control among women of childbearing age in Hossana Town, Hadiya zone, Southern Ethiopia: Community-based cross-sectional study.
    PLoS One. 2017;12:e0181415.
    PubMed     Abstract available


  200. SIGFRID L, Murphy G, Haldane V, Chuah FLH, et al
    Integrating cervical cancer with HIV healthcare services: A systematic review.
    PLoS One. 2017;12:e0181156.
    PubMed     Abstract available


  201. CHONGTHAWONSATID S
    Inequity of healthcare utilization on mammography examination and Pap smear screening in Thailand: Analysis of a population-based household survey.
    PLoS One. 2017;12:e0173656.
    PubMed     Abstract available


  202. JIANG Y, Chen C, Li L
    Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis.
    PLoS One. 2017;12:e0170587.
    PubMed     Abstract available


  203. NOGUEIRA DIAS GENTA ML, Martins TR, Mendoza Lopez RV, Sadalla JC, et al
    Multiple HPV genotype infection impact on invasive cervical cancer presentation and survival.
    PLoS One. 2017;12:e0182854.
    PubMed     Abstract available


  204. KELLY HA, Ngou J, Chikandiwa A, Sawadogo B, et al
    Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa.
    PLoS One. 2017;12:e0174117.
    PubMed     Abstract available


  205. DEL MISTRO A, Frayle H, Rizzi M, Fantin G, et al
    Methylation analysis and HPV genotyping of self-collected cervical samples from women not responding to screening invitation and review of the literature.
    PLoS One. 2017;12:e0172226.
    PubMed     Abstract available


  206. DE GROOT AS, Tounkara K, Rochas M, Beseme S, et al
    Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali.
    PLoS One. 2017;12:e0171631.
    PubMed     Abstract available


  207. LEVENTAKOS K, Tsiodras S, Kelesidis T, Kefala M, et al
    gammaH2Ax Expression as a Potential Biomarker Differentiating between Low and High Grade Cervical Squamous Intraepithelial Lesions (SIL) and High Risk HPV Related SIL.
    PLoS One. 2017;12:e0170626.
    PubMed     Abstract available


  208. SIMMS KT, Hall M, Smith MA, Lew JB, et al
    Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
    PLoS One. 2017;12:e0163509.
    PubMed     Abstract available


  209. PALATNIK A, Ye S, Kendziorski C, Iden M, et al
    Identification of a serum-induced transcriptional signature associated with metastatic cervical cancer.
    PLoS One. 2017;12:e0181242.
    PubMed     Abstract available


  210. GARBA RM, Gadanya MA
    The role of intervention mapping in designing disease prevention interventions: A systematic review of the literature.
    PLoS One. 2017;12:e0174438.
    PubMed     Abstract available


  211. AZZOLLINI J, Pesenti C, Ferrari L, Fontana L, et al
    Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.
    PLoS One. 2017;12:e0171663.
    PubMed     Abstract available


  212. RHODES CM, Chang Y, Regan S, Triant VA, et al
    Non-Communicable Disease Preventive Screening by HIV Care Model.
    PLoS One. 2017;12:e0169246.
    PubMed     Abstract available


  213. LU Y, Wei JY, Yao DS, Pan ZM, et al
    Application of carbon nanoparticles in laparoscopic sentinel lymph node detection in patients with early-stage cervical cancer.
    PLoS One. 2017;12:e0183834.
    PubMed     Abstract available


  214. MUSA J, Achenbach CJ, O'Dwyer LC, Evans CT, et al
    Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0183924.
    PubMed     Abstract available


  215. GININDZA TG, Sartorius B, Dlamini X, Ostensson E, et al
    Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
    PLoS One. 2017;12:e0177762.
    PubMed     Abstract available


  216. JOO JH, Kim YS, Cho BC, Jeong CY, et al
    Variability in target delineation of cervical carcinoma: A Korean radiation oncology group study (KROG 15-06).
    PLoS One. 2017;12:e0173476.
    PubMed     Abstract available


  217. ELMI AA, Bansal D, Acharya A, Skariah S, et al
    Human Papillomavirus (HPV) Infection: Molecular Epidemiology, Genotyping, Seroprevalence and Associated Risk Factors among Arab Women in Qatar.
    PLoS One. 2017;12:e0169197.
    PubMed     Abstract available


  218. MEISAL R, Rounge TB, Christiansen IK, Eieland AK, et al
    HPV Genotyping of Modified General Primer-Amplicons Is More Analytically Sensitive and Specific by Sequencing than by Hybridization.
    PLoS One. 2017;12:e0169074.
    PubMed     Abstract available


  219. BERNAUDO S, Khazai S, Honarparvar E, Kopteva A, et al
    Epidermal growth factor promotes cyclin G2 degradation via calpain-mediated proteolysis in gynaecological cancer cells.
    PLoS One. 2017;12:e0179906.
    PubMed     Abstract available


  220. SLOTTA C, Schluter T, Ruiz-Perera LM, Kadhim HM, et al
    CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle.
    PLoS One. 2017;12:e0182373.
    PubMed     Abstract available


  221. XI J, Chen J, Xu M, Yang H, et al
    Genetic variability and functional implication of the long control region in HPV-16 variants in Southwest China.
    PLoS One. 2017;12:e0182388.
    PubMed     Abstract available


  222. SABOL I, Milutin Gasperov N, Matovina M, Bozinovic K, et al
    Cervical HPV type-specific pre-vaccination prevalence and age distribution in Croatia.
    PLoS One. 2017;12:e0180480.
    PubMed     Abstract available


  223. YANEZ RJR, Lamprecht R, Granadillo M, Weber B, et al
    Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana.
    PLoS One. 2017;12:e0183177.
    PubMed     Abstract available


  224. ZHANG L, Xie F, Wang X, Peng D, et al
    Previous cervical cytology and high-risk human papillomavirus testing in a cohort of patients with invasive cervical carcinoma in Shandong Province, China.
    PLoS One. 2017;12:e0180618.
    PubMed     Abstract available


  225. MCGRATH CJ, Garcia R, Trinh TT, Richardson BA, et al
    Role of p16 testing in cervical cancer screening among HIV-infected women.
    PLoS One. 2017;12:e0185597.
    PubMed     Abstract available


  226. BINKA C, Doku DT, Awusabo-Asare K
    Experiences of cervical cancer patients in rural Ghana: An exploratory study.
    PLoS One. 2017;12:e0185829.
    PubMed     Abstract available


  227. UEDA A, Takasawa A, Akimoto T, Takasawa K, et al
    Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix.
    PLoS One. 2017;12:e0184123.
    PubMed     Abstract available


  228. BOTWRIGHT S, Holroyd T, Nanda S, Bloem P, et al
    Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
    PLoS One. 2017;12:e0182663.
    PubMed     Abstract available


  229. STANISAVLJEVIC D, Petrovic I, Vukovic V, Schwirtlich M, et al
    SOX14 activates the p53 signaling pathway and induces apoptosis in a cervical carcinoma cell line.
    PLoS One. 2017;12:e0184686.
    PubMed     Abstract available


  230. KWAK YK, Lee SW, Kay CS, Park HH, et al
    Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose.
    PLoS One. 2017;12:e0183339.
    PubMed     Abstract available


  231. HU X, Li S, Zhou L, Zhao M, et al
    Effect of vitamin E supplementation on uterine cervical neoplasm: A meta-analysis of case-control studies.
    PLoS One. 2017;12:e0183395.
    PubMed     Abstract available


  232. SCHMID BC, Carlson J, Rezniczek GA, Wyllie J, et al
    Examining word association networks: A cross-country comparison of women's perceptions of HPV testing and vaccination.
    PLoS One. 2017;12:e0185669.
    PubMed     Abstract available


  233. CARNEIRO SR, Fagundes MA, do Rosario PJO, Neves LMT, et al
    Five-year survival and associated factors in women treated for cervical cancer at a reference hospital in the Brazilian Amazon.
    PLoS One. 2017;12:e0187579.
    PubMed     Abstract available


  234. ANANTHARAJU PG, Reddy DB, Padukudru MA, Chitturi CMK, et al
    Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC).
    PLoS One. 2017;12:e0186208.
    PubMed     Abstract available


  235. DENIZ S, Kurt B, Oguzoncul AF, Nazlican E, et al
    Knowledge, attitudes and behaviours of women regarding breast and cervical cancer in Malatya, Turkey.
    PLoS One. 2017;12:e0188571.
    PubMed     Abstract available


  236. SENAPATI R, Nayak B, Kar SK, Dwibedi B, et al
    HPV genotypes co-infections associated with cervical carcinoma: Special focus on phylogenetically related and non-vaccine targeted genotypes.
    PLoS One. 2017;12:e0187844.
    PubMed     Abstract available


  237. ROIK EE, Sharashova EE, Nieboer E, Kharkova OA, et al
    Knowledge about human papillomavirus and prevention of cervical cancer among women of Arkhangelsk, Northwest Russia.
    PLoS One. 2017;12:e0189534.
    PubMed     Abstract available


  238. ZHOU Z, Li W, Zhang F, Hu K, et al
    The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review.
    PLoS One. 2017;12:e0186165.
    PubMed     Abstract available



  239. Correction: Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0190661.
    PubMed     Abstract available


  240. ANDERSSON S, Belkic K, Demirbuker SS, Mints M, et al
    Perceived cervical cancer risk among women treated for high-grade cervical intraepithelial neoplasia: The importance of specific knowledge.
    PLoS One. 2017;12:e0190156.
    PubMed     Abstract available


  241. DA SILVA ERP, de Souza AS, de Souza TGB, Tsuha DH, et al
    Screening for cervical cancer in imprisoned women in Brazil.
    PLoS One. 2017;12:e0187873.
    PubMed     Abstract available


    January 2016
  242. CHANTHAVILAY P, Reinharz D, Mayxay M, Phongsavan K, et al
    Economic Evaluation of Screening Strategies Combined with HPV Vaccination of Preadolescent Girls for the Prevention of Cervical Cancer in Vientiane, Lao PDR.
    PLoS One. 2016;11:e0162915.
    PubMed     Abstract available


  243. HUANG Y, Li Y, Wang FF, Lv W, et al
    Over-Expressed miR-224 Promotes the Progression of Cervical Cancer via Targeting RASSF8.
    PLoS One. 2016;11:e0162378.
    PubMed     Abstract available


  244. REN J, Yuan W, Wang R, Wang Q, et al
    Dosimetric Comparison between Three-Dimensional Magnetic Resonance Imaging-Guided and Conventional Two-Dimensional Point A-Based Intracavitary Brachytherapy Planning for Cervical Cancer.
    PLoS One. 2016;11:e0161932.
    PubMed     Abstract available


  245. LIU S, Song L, Yao H, Zhang L, et al
    MiR-375 Is Epigenetically Downregulated by HPV-16 E6 Mediated DNMT1 Upregulation and Modulates EMT of Cervical Cancer Cells by Suppressing lncRNA MALAT1.
    PLoS One. 2016;11:e0163460.
    PubMed     Abstract available


  246. MITIKU I, Tefera F
    Knowledge about Cervical Cancer and Associated Factors among 15-49 Year Old Women in Dessie Town, Northeast Ethiopia.
    PLoS One. 2016;11:e0163136.
    PubMed     Abstract available


  247. CAMPOS NG, Sharma M, Clark A, Kim JJ, et al
    Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries.
    PLoS One. 2016;11:e0164000.
    PubMed     Abstract available


  248. ZHOU H, Wang Y, Lv Q, Zhang J, et al
    Overexpression of Ribosomal RNA in the Development of Human Cervical Cancer Is Associated with rDNA Promoter Hypomethylation.
    PLoS One. 2016;11:e0163340.
    PubMed     Abstract available


  249. ZHANG L, Qian H, Sha M, Luan Z, et al
    Downregulation of HOTAIR Expression Mediated Anti-Metastatic Effect of Artesunate on Cervical Cancer by Inhibiting COX-2 Expression.
    PLoS One. 2016;11:e0164838.
    PubMed     Abstract available


  250. GAO D, Zhang Y, Zhu M, Liu S, et al
    miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China.
    PLoS One. 2016;11:e0164701.
    PubMed     Abstract available


  251. STEFANOWICZ-HAJDUK J, Sparzak-Stefanowska B, Krauze-Baranowska M, Ochocka JR, et al
    Securinine from Phyllanthus glaucus Induces Cell Cycle Arrest and Apoptosis in Human Cervical Cancer HeLa Cells.
    PLoS One. 2016;11:e0165372.
    PubMed     Abstract available


  252. LI J, Wu MF, Lu HW, Zhang BZ, et al
    Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer.
    PLoS One. 2016;11:e0166612.
    PubMed     Abstract available


  253. RASHID S, Labani S, Das BC
    Knowledge, Awareness and Attitude on HPV, HPV Vaccine and Cervical Cancer among the College Students in India.
    PLoS One. 2016;11:e0166713.
    PubMed     Abstract available


  254. HUANG B, Cai J, Xu X, Guo S, et al
    High-Grade Tumor Budding Stratifies Early-Stage Cervical Cancer with Recurrence Risk.
    PLoS One. 2016;11:e0166311.
    PubMed     Abstract available


  255. ALFARO A, Juarez-Torres E, Medina-Martinez I, Mateos-Guerrero N, et al
    Different Association of Human Papillomavirus 16 Variants with Early and Late Presentation of Cervical Cancer.
    PLoS One. 2016;11:e0169315.
    PubMed     Abstract available


  256. ZHENG Q, Wang T, Jiang S, Han R, et al
    Production of Polyclonal Antibody to the HPV58 E7 Protein and Its Detection in Cervical Cancer.
    PLoS One. 2016;11:e0169138.
    PubMed     Abstract available


  257. SHARFO AW, Breedveld S, Voet PW, Heijkoop ST, et al
    Validation of Fully Automated VMAT Plan Generation for Library-Based Plan-of-the-Day Cervical Cancer Radiotherapy.
    PLoS One. 2016;11:e0169202.
    PubMed     Abstract available


  258. MARIANO VS, Lorenzi AT, Scapulatempo-Neto C, Stein MD, et al
    A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
    PLoS One. 2016;11:e0164892.
    PubMed     Abstract available


  259. WANG L, Wang P, Ren Y, Du J, et al
    Prevalence of High-Risk Human Papillomavirus (HR-HPV) Genotypes and Multiple Infections in Cervical Abnormalities from Northern Xinjiang, China.
    PLoS One. 2016;11:e0160698.
    PubMed     Abstract available


  260. KHUNAMORNPONG S, Settakorn J, Sukpan K, Suprasert P, et al
    Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.
    PLoS One. 2016;11:e0158184.
    PubMed     Abstract available


  261. SMELOV V, Gheit T, Sundstrom K, Ploner A, et al
    Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study.
    PLoS One. 2016;11:e0156215.
    PubMed     Abstract available


  262. SETIAWAN D, Kotsopoulos N, Wilschut JC, Postma MJ, et al
    Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach.
    PLoS One. 2016;11:e0160707.
    PubMed     Abstract available


  263. MOLBAK K, Hansen ND, Valentiner-Branth P
    Pre-Vaccination Care-Seeking in Females Reporting Severe Adverse Reactions to HPV Vaccine. A Registry Based Case-Control Study.
    PLoS One. 2016;11:e0162520.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: